×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VSTM – verastem, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VSTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/11
01:00 am
vstm
Verastem (VSTM) was downgraded by Wall Street Zen from "hold" to "sel
Medium
Report
Verastem (VSTM) was downgraded by Wall Street Zen from "hold" to "sel
4/10
01:53 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
4/10
01:29 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
4/10
07:00 am
vstm
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Medium
Report
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
4/2
04:05 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/30
11:54 am
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
3/19
03:33 pm
vstm
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
Low
Report
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
3/17
06:03 pm
vstm
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Low
Report
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/9
04:15 pm
vstm
Form DEF 14A Verastem, Inc. For: May 21
Medium
Report
Form DEF 14A Verastem, Inc. For: May 21
3/27
01:52 pm
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: VANGUARD GROUP INC
3/23
05:20 pm
vstm
Form 4 Verastem, Inc. For: Mar 20 Filed by: Calkins Daniel
Medium
Report
Form 4 Verastem, Inc. For: Mar 20 Filed by: Calkins Daniel
3/4
04:16 pm
vstm
Form 8-K Verastem, Inc. For: Mar 04
Medium
Report
Form 8-K Verastem, Inc. For: Mar 04
3/4
04:06 pm
vstm
Form 10-K Verastem, Inc. For: Dec 31
Medium
Report
Form 10-K Verastem, Inc. For: Dec 31
2/17
09:43 pm
vstm
Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
2/17
04:35 pm
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Point72 Asset Management, L.P.
2/17
08:54 am
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
Low
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
59.4%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
TOP News Decliners
4/27
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
-51.4%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: